Nilutamide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nilutamide
Nilutamide.svg
Systematic (IUPAC) name
5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]
imidazolidine-2,4-dione
Clinical data
Trade names Nilandron
AHFS/Drugs.com monograph
MedlinePlus a697044
Legal status pr
Routes oral
Pharmacokinetic data
Half-life 38.0 to 59.1 hours
Identifiers
CAS number 63612-50-0 YesY
ATC code L02BB02
PubChem CID 4493
IUPHAR ligand 2864
DrugBank DB00665
ChemSpider 4337 YesY
UNII 51G6I8B902 YesY
KEGG D00965 YesY
ChEBI CHEBI:7573 YesY
ChEMBL CHEMBL1274 YesY
Chemical data
Formula C12H10F3N3O4 
Mol. mass 317.221 g/mol
 YesY (what is this?)  (verify)

Nilutamide is an antiandrogen medication used in the treatment of advanced-stage prostate cancer. Nilutamide blocks the androgen receptor, preventing its interaction with testosterone. Because most prostate cancer cells rely on the stimulation of the androgen receptor for growth and survival, nilutamide can prolong life in men with prostate cancer. Nilutamide is marketed under the name Nilandron in the United States and under the name Anandron in Canada.

See also[edit]

References[edit]

  • Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J. Urol. 2003 May;169(5):1742-4. PMID 12686822
  • Moguilewsky M, Bertagna C, Hucher M. (1987) Pharmacological and clinical studies of the antiandrogen Anandron (nilutamide). J Steroid Biochem. (4-6):871-5.
  • Hsieh AC, Ryan CJ. (2008) Novel concepts in androgen receptor blockade. Cancer J. 14(1):11-14.